IQVIA (NYSE:IQV) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of IQVIA (NYSE:IQV) from a hold rating to a buy rating in a research report sent to investors on Saturday morning,Wall Street Zen reports.

Several other equities research analysts also recently weighed in on the company. Mizuho raised their price target on IQVIA from $215.00 to $230.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. Weiss Ratings raised shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, July 15th. Deutsche Bank Aktiengesellschaft set a $240.00 target price on shares of IQVIA in a research note on Thursday, July 9th. Robert W. Baird raised their price target on shares of IQVIA from $252.00 to $287.00 and gave the stock an “outperform” rating in a report on Wednesday, July 29th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of IQVIA from $225.00 to $285.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $243.62.

IQVIA Stock Up 1.5%

Shares of NYSE IQV opened at $265.79 on Friday. IQVIA has a 12-month low of $154.50 and a 12-month high of $271.80. The stock’s fifty day simple moving average is $237.75 and its two-hundred day simple moving average is $196.87. The stock has a market capitalization of $43.75 billion, a PE ratio of 32.98, a price-to-earnings-growth ratio of 2.24 and a beta of 1.18. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. The business had revenue of $4.37 billion for the quarter, compared to the consensus estimate of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The business’s quarterly revenue was up 8.7% on a year-over-year basis. During the same period in the prior year, the firm posted $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, analysts expect that IQVIA will post 11.57 EPS for the current fiscal year.

Insiders Place Their Bets

In other IQVIA news, insider Keriann Cherofsky sold 558 shares of the company’s stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $245.21, for a total value of $136,827.18. Following the sale, the insider directly owned 2,989 shares of the company’s stock, valued at approximately $732,932.69. This represents a 15.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Bhavik Patel sold 1,855 shares of the stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $235.27, for a total value of $436,425.85. Following the sale, the insider directly owned 1,348 shares in the company, valued at $317,143.96. This represents a 57.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 15,581 shares of company stock worth $3,796,021. Company insiders own 1.70% of the company’s stock.

Institutional Investors Weigh In On IQVIA

Several hedge funds have recently bought and sold shares of IQV. Apella Capital LLC boosted its holdings in shares of IQVIA by 5.1% during the 1st quarter. Apella Capital LLC now owns 1,196 shares of the medical research company’s stock worth $211,000 after purchasing an additional 58 shares during the last quarter. Breakwater Capital Group increased its holdings in shares of IQVIA by 3.2% in the second quarter. Breakwater Capital Group now owns 2,073 shares of the medical research company’s stock valued at $401,000 after purchasing an additional 64 shares during the last quarter. First Growth Capital LLC lifted its position in IQVIA by 3.2% during the first quarter. First Growth Capital LLC now owns 2,173 shares of the medical research company’s stock worth $375,000 after buying an additional 68 shares in the last quarter. Root Financial Partners LLC lifted its position in IQVIA by 31.0% during the fourth quarter. Root Financial Partners LLC now owns 296 shares of the medical research company’s stock worth $67,000 after buying an additional 70 shares in the last quarter. Finally, Chicago Partners Investment Group LLC boosted its stake in IQVIA by 1.5% during the first quarter. Chicago Partners Investment Group LLC now owns 4,635 shares of the medical research company’s stock worth $812,000 after buying an additional 70 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

About IQVIA

IQVIA Holdings Inc is a global provider of advanced analytics, technology solutions and contract research services for the life sciences industry. The company supports pharmaceutical, biotechnology and medical device companies throughout the product life cycle, from research and clinical development through commercialization and post-market activities.

Its offerings include clinical trial management, site and patient services, real-world evidence, healthcare data, regulatory and safety services, commercial analytics, consulting, and technology platforms.